- Home
- About
- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Events
- Resource Center
- PKD & Rare Kidney Diseases
- Anemia Due To CKD
- CKD & Related Comorbid Conditions
- Kidney Failure & Kidney Replacement Therapies
- Electrolyte Disorders
- NephU Nutrition & The NephChefTM
- NephU Presents – Hot Topics in Nephrology
- NephU Med Talks
- Tools
Archives
Drink Up! How Much Water Is Enough In The Management Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)?
About This Event
Drink Up! How Much Water Is Enough In The Management Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)?
Please join us as we discuss recent clinical data on water intake practices, feasibility of conducting water trials, and results of a randomized controlled trial of prescribed water intake in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In this presentation the impact of water intake on ADPKD disease progression including Total Kidney Volume (TKV) will be discussed.
Featuring
Andrea Noto, PharmD
Nephrology Clinical & Scientific LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Andrea Noto, PharmD, is a Nephrology Clinical & Scientific Liaison covering New York City & Long Island. She earned her PharmD at the University of Rhode Island in South Kingstown, RI. Prior to joining Otsuka in 2021, Dr Noto held various leadership roles in retail pharmacy for 15 years in the NJ and NYC regions. Most recently, she held the role of Doctor Partnership Manager for a retail pharmacy startup company and worked closely with Psychiatrists and Migraine Specialists. She is currently licensed in New Jersey and New York state.
Molly Jansen, PhD
Nephrology Clinical & Scientific LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*
Dr Molly Jansen is a Nephrology Clinical & Scientific Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas and New Mexico. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.
*Drs Noto and Jansen are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
If you would like to register for the 9:00 pm to 10:00 pm EDT broadcast, please click below:
Registration
Please Log In Or Join to Register for this Event.
Related Resources
-
Infographic – The “Four Hit” IgA Nephropathy (IgAN) Pathogenesis Theory
Infographic May 13, 2022This infographic reviews the four hit pathogenesis theory for IgA Nephropathy (IgAN).
-
Infographic – The Impact Of Daily Caloric Restriction (DCR) Vs. Intermittent Fasting (IMF) On Weight Loss & Autosomal Dominant Polycystic Kidney Disease (ADPKD) Outcomes
Infographic March 11, 2022This infographic reviews some of the information pertaining to daily caloric restriction versus intermittent fasting in relation to weight loss and ADPKD outcomes.
-
On-Demand Webinar – Nephronophthisis (NPHP) & Related Rare Cystic Kidney Diseases
On-Demand Webinar February 24, 2022Enjoy this on-demand NephU webinar where we are joined by experts, Carl Bates, MD and Rannar Airik, PhD who will describe nephronophthisis (NPHP), the most frequent genetic cause for end-stage…
Related Events
-
Drink Up! How Much Water Is Enough In The Management Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)?
May 25 from 9:00 pm to 10:00 pm -
Recognizing The Inner Voice: Breaking The LGBTQIA+ Conversation Barrier
June 1 from 12:00 pm to 1:00 pm
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2021 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.